NCT06818955View on ClinicalTrials.gov

Orlistat Overcoming Third-generation EGFR-TKI Resistance

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 16, 2025

Primary Completion Date

May 15, 2025

Study Completion Date

November 15, 2025

Conditions
Lung AdenocarcinomaOsimertinib
Interventions
DRUG

Orlistat 120 mg

Orlistat 120 mg po tid

All Listed Sponsors
collaborator

Hubei Cancer Hospital

OTHER

lead

Ping Peng

OTHER